Research & Development
Immunocore’s mTCRs are biological targeting proteins with binding affinities very similar to monoclonal antibodies, but with the advantage of being able to target cells based on intracellular protein targets. However, unlike traditional antibodies, soluble mTCRs do not possess an in-built killing function; Immunocore expresses its mTCRs as fusion proteins to known potent biological effector functions, such as anti-CD3 binding domains for cancer or cytokines for autoimmune disease. In this regard, they can be thought of as similar to antibody drug conjugates.
Overall, this ability to target tissues with a variety of effector function payloads means that mTCRs can be used to treat a disparate range of indications using the same core platform technology.